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ABSTRACT
OPTIONS FOR LOW-COST MANUFACTURING AND SAFER CELL THERAPIES
by Melis Keceli
The proposed work aims to overcome the economical and feasibility-related
limitations of the chimeric antigen receptor therapies by developing an artificial cell
signaling pathway whose design transforms K562 cells into in vivo living vectors to
synthesize therapeutic proteins upon engaging diseased cells in the treatment of ovarian
cancer. There are various advantages of using K562 cells throughout this process. First,
Food and Drug Administration approves the reinfusion of K562 cells into patients’
bodies. Second, K562 cells are more affordable than T lymphocytes, and finally, these
cells can be easily manipulated with any desired genetic material and can keep the
expression of engineered genes stable. However, they do not express a chemokine
receptor, a type of cytokine controlling the traffic of the immune cells to a desired site of
the body. Therefore, these cells must be manipulated with chemokine receptors to enable
them to migrate directly towards the tumor microenvironment to prevent harm to the
healthy parts of the body. For the manipulation of all cells used in this study, lentiviruses
were produced to transduce them. Nanoluc luciferase reporter was used as an effector
protein to evaluate whether K562 cells can synthesize these enzymes in situ upon
interacting with diseased cells. K562 cells lack necessary molecules that would drive
them to form an immunological synapse to produce engineered proteins. As a result,
they were not able to produce the Nanoluc enzyme. On the other hand, this study shows
that the chemokine system presents an excellent potential for immunotherapies, and it
may help prevent damage to healthy tissue.
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1 Introduction
The oldest description of cancer dates back to about 3000 BC and is found in ancient
Egyptian manuscripts. Cancer is the second leading cause of death, behind heart diseases,

in the United States, and the World Health Organization (WHO) attributes an estimated
9.6 million deaths to cancer worldwide (1). Research into the risk factors for developing
cancer is considered a priority. Several factors have been identified: cancer can be
hereditary, or it can occur because of ‘lifestyle factors, including but not limited to
tobacco smoke, alcohol consumption, and excessive sun or radiation exposure (2).
The treatments currently available for cancer include surgery, chemotherapy,
radiation therapy, and immunotherapy. The selection of treatment is dependent on the
type of cancer and its location, as well as how advanced it is. Some patients may receive
only one type of therapy, while others receive a combination simultaneously or in
sequence. The treatment goal is to eradicate as many tumor cells as possible while
minimizing the harm to the surrounding healthy cells. However, all treatments have
potential disadvantages and have the potential to cause harm. For example,
chemotherapy, radiation therapy, and surgery may damage nearby tissues or may be
unable to kill all the cancerous cells. Thus, it should be noted that none of these therapies
may be able to cure cancer completely (3).
Immunotherapy is an emerging area of cancer research that shows tremendous
advantages in relation to increasing survival rates and the maintenance of patients’ life
quality when compared to the other types of treatments mentioned above (4).
Immunotherapy is a biological therapy that teaches the body’s immune system to fight
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cancer. There are two lines of defense of the body against foreign substances: innate
immunity and adaptive immunity. Innate immunity is the first line of defense and is
present from birth, protecting the body from infections even before they start. Most
infections can be stopped by innate immunity. However, if they cannot, the second line of
defense, adaptive immunity, becomes active. As such, lymphocytes, the key elements of
adaptive immunity, would recognize pathogens with their cell surface antigens and
proliferate to clear the body of foreign substances (5,6). Lymphocytes are mainly divided
into T lymphocytes and B lymphocytes. While B lymphocytes are programmed to
produce antibodies, T lymphocytes are programmed to recognize antigens and respond to

them (7). T lymphocytes have T cell receptors (TCRs) on their cell surface that would
allow them to engage the major histocompatibility complex (MHC) on the target diseased
cells. MHC is a genetic system that binds peptide fragments of pathogens and expresses

them on the cell surface to be recognized and destroyed by immune cells. However, many
cancer cells do not express MHCs on their cell surface as a result of an evolutionary
mechanism, avoiding immune cells and spreading to other parts of the body (6,8). To

overcome this limitation, scientists manipulate patients’ T cells with a protein called
chimeric antigen receptor (CAR). CARs enable T cells to bind cancer cells even though
they don’t have MHCs on their surface (9).
In CAR T cell therapy, a patient’s white blood cells are collected, and the T cells are
separated. These T cells are then genetically engineered in a laboratory to express CARs
on their cell surface and are then grown into the hundreds of millions to be given to the
patient by infusion. The CARs enable T cells to bind to the antigens on cancer cells and
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kill them (10). Since each cancer type has its specific antigen, CARs must be specific and
generated for each cancer type respectively to attach to the different receptors of different
cancer cells. CAR T cell therapy is a process in which each patient’s immune cells are
meticulously treated and engineered to express specific receptors depending on the
cancer type. However, Primary T cells are highly challenging to grow in the laboratory as
they need to be activated first. Given these challenges, CAR T cell therapies are costly
and not affordable for many cancer patients, even though there are two approved CAR T
cell therapies by Food and Drug Administration (FDA). The two treatments, Kymriah
and Yescarta, cost $475,000 and $373,000, respectively (11). As a result of being very

expensive, a cheaper alternative to CAR T cell therapy must be found to provide more
affordable and accessible treatments for cancer patients.
Further to high treatment costs, current protein-based cancer therapies have side

effects, such as systemic toxicity, and the dose-response relationship varies from patient
to patient. To overcome these limitations, T cell biofactory technology represents a great
potential to synthesize and deliver appropriate amounts of therapeutic proteins for cell-

based diseases like cancer, viral infections, and autoimmune diseases. T cell biofactory
technology refers to developing an artificial cell-signaling pathway whose design
transforms a T cell into a living vector that would synthesize engineered therapeutic
proteins during the engagement with the antigen-presenting target cells. Reprogramming
of a biofactory to recognize different targets depending on the cancer type or disease type
is also possible. A previous study performed by Bhatnagar et al. (45) showed that T cell
biofactory has a great potential for targeting diseased cells with maximal specificity. This
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technology was first applied to Jurkat cells (12). Jurkat cells, an immortalized line of T
cells, have all the machinery that Primary T cells have, except they are cancer cells.
Jurkat cells are preferred for new application evaluation because their culture and growth
in the laboratory are more manageable compared to Primary T cells. Although this
system has worked, and Jurkat cells have produced the engineered proteins, it is not
possible to reinfuse Jurkat cells into the patient’s body as they are cancer cells. Also,
implementing this system in Primary T cells would cause the therapy to be costly, which
is unlikely accessible for all cancer patients. Also, for the best results of this therapy, the
effector cells must migrate directly to the diseased cells. To do this, T cells are

engineered to express chemokine receptors that drive them to the site of infection in the
body. Chemokines, being chemotactic cytokines, control the homing, retention, and
migration of immune cells towards the tumor microenvironment (13). Thus, the

chemokine system represents a potential target for CAR T cell therapies as it enables
effector cells to go directly to target cells.
In order to find a cheaper alternative to CAR T cell therapies, one of the aims of this
study was to test if K562 cells can be used as a cellular chassis for developing a
biofactory technology to produce therapeutic proteins for ovarian cancer. It is important
to note that it is possible to replace the antibodies that recognize antigens and the proteins
that can be synthesized in situ upon the engagement of effector and target cells,
depending on the disease type. Therefore, biofactory technology has a great potential for
targeting different cell-based diseases. The rationale for choosing the K562 cell line is
that it has been clinically approved to be safely administered to patients with acute
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myeloid leukemia after being genetically modified, and it is cheaper and easier to expand
than Primary T cells. As the price of CAR T cell therapies is an obvious barrier, this
study may result in economic benefits. Another aim of this study was to test the
hypothesis that Jurkat cells migrate directly to the tumor microenvironment. Neither
Jurkat nor K562 express chemokine receptors. As a result, these cells may target and
harm healthy parts of the body after reinfusion. Therefore, to have effector cells migrate
directly to the diseased site, Jurkat cells were engineered to express appropriate
chemokine receptors whose corresponding chemokines were produced in the ovarian
tumor microenvironment. If Jurkat cells successfully migrate towards the tumor cells, the
same system can be implemented in K562 biofactories in later studies. This
implementation would provide safer therapy in which K562 biofactories directly migrate
towards the tumor microenvironment without harming the healthy cells.
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2 Literature Review
This literature review first discusses different types of cancer immunotherapy,
building background information. Second, CAR T cell therapies and their challenges are
addressed to indicate the need for this study. Third, the importance of forming an
immunological synapse and chemokine system for T cells’ migration, differentiation, and
activation is discussed. Finally, different viral gene delivery techniques for delivering
genetic material to CAR T cells are reviewed.
2.1 Cancer Immunotherapy
Immunotherapy, also known as biological therapy, is the fight of our immune cells
against cancerous cells (4). Dr. William Coley, known as the father of immunotherapy,
was moved to research immunotherapies for cancerous tumors after a 17-year-old patient,
who did not recover and died weeks later despite the amputation of the sarcoma. Coley
documented his successes through experimentation and published case series, achieving
remission for sarcoma, lymphoma, and testicular cancer. However, his method was met
with initial skepticism, and other oncologists were concerned about deliberately injecting
patients with pathogenic bacteria to treat malignant cells (14).
Since Coley’s early work, immunotherapy has progressed significantly, and there are
now multiple types of immunotherapies available. One such method is adoptive T cell
therapy, also known as cellular adoptive immunotherapy or T cell transfer therapy (7).
There are three types of adoptive T cell therapy; tumor-infiltrating lymphocyte (TIL)
therapy, engineered T cell receptor (TCR) therapy, and chimeric antigen receptor T cell
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(CAR T cell) therapy. Researchers have recently begun to incorporate natural killer cells,
another type of immune cell, for an alternative adoptive therapy (15).
TIL therapy was pioneered in the late 1980s to treat metastatic melanoma. In this type
of therapy, T cells are isolated from a patient’s tumor and expanded ex vivo with
interleukin 2 (IL-2), a type of cytokine that enhances T cells’ activation and contributes
to their differentiation into effector T cells (15,16). The effector T cells are then infused
intravenously into the patient’s body. Even though studies show promising results, not
every patient has T cells recognizing their tumors, meaning such patients’ T cells cannot
bind to antigens and destroy cancer cells. To address this challenge and support a wider
range of cancer patients, TCR therapy has been developed. In TCR therapy, patients’ T
cells are isolated too, but instead of just activation and expansion, doctors and scientists
can manipulate T cells and target specific tumor antigens. Once manipulated, T cells are
grown in the laboratory and are then reinfused into the patient’s bloodstream. This
method provides more personalized treatments compared to TIL therapy (7,15).
Although these two therapies have led clinical oncologists to expect more significant
tumor regression, results have been disappointing and below expectations. One
explanation for the lackluster results may be the downregulation of major
histocompatibility complex I (MHC-I) on the tumor surface. The downregulation of
MHCs causes cancer cells not to be recognized and destroyed by T cells. Therefore,
cancer cells can grow and spread to other parts of the body (8). To have promising results
from TCR therapy, MHC or human leukocyte antigen complex (HLA complex), a
chromosomal region with different genes, must present intracellular tumor-related
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antigens on cancer cells’ surface to TCRs on T cells (5). MHC-I or MHC-II should be
present on the cancer cells’ surface to be detected or destroyed by immune cells (8). To
overcome this limitation, scientists equip patients’ T cells with a protein called chimeric
antigen receptors (CARs). CARs enable T cells to bind to cancer cells despite not having
MHCs on their surface and enable immune cells to better identify cancer cell antigens.
Since each cancer type has its specific antigen, each CAR is generated specifically for
each cancer type. CAR T cells contain extracellular, intracellular, and transmembrane
regions. Whereas the extracellular region has a single-chain variable fragment (scFv)
domain to recognize tumor-associated antigens, the intracellular domain is composed of
immunoreceptor tyrosine-based activation motif (ITAM) of the cluster of differentiation3 zeta (CD3ζ), which activates co-stimulatory molecules (9,17).
2.2 CAR T Cell Therapies
CAR is a hybrid antigen receptor, which includes a part of an antibody and a part of a
TCR. The antibody part is found in the transmembrane domain, and the T cell receptor
part is found in the intracellular domain. The antibody part of CAR enables it to bind to
an antigen, and the TCR part helps activate the CAR when encountering antigenpresenting cells (18). Over the past years, there have been five generations of CAR T
cells, which have been generated to target a specific protein independent of MHC Class I
or MHC Class II, which depends upon the type of T cell (either CD8+ or CD4+ T
lymphocyte, respectively) on an antigen-presenting cell’s surface (9,17).
In 1993, Eshhar et al. were the first to show the first-generation CARs, consisting of
scFv extracellular domain as an antigen recognition motif and a cluster of differentiation-
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3 zeta (CD3ζ) ITAM domain as an activation motif. They expected these CARs would
promote IL-2 secretion upon encountering cancer cells independent of MHC (19).
However, two years later, Brocker et al. found that resting T cells and effector T cells had
different signaling capabilities. The chimeric receptor ζ, which would activate T cells,
expressed by transgenic mice was not sufficient to activate resting T cells. Nevertheless,
if the T cells were preactivated, the chimeric receptor ζ was able to activate them. Also,
the activated T cells were able to proliferate and had cytotoxic effects upon encountering
antigen-presenting cells (20).
In the late 1990s, Gong et al. conducted a study with patients at different stages of
prostate cancer. They showed that if T cells were engineered to express the Pz-1 receptor,
which lyses prostate cancer cells, they could release cytokines and target tumor cells (21).
Upon completion of these studies (19, 20), it was concluded that the first-generation of
CAR T cells had insufficient proliferation, secretion of cytokines, and cytotoxic activity
in vivo (22).
Going forward, co-stimulatory molecules identified as vital for T cell activation,
proliferation, and survival were added to second and third-generation CARs. T cell
activation needs two signals, one from a TCR and the other from a co-stimulatory
molecule such as CD28. This co-stimulatory molecule improves IL-2 synthesis, a
cytokine necessary for the T cell stimulation, as proved by Finney et al (23). Thus, the
absence of co-stimulatory molecules prevents naive T cells' functions, which would lead
to T cells' anergy (24, 25). The co-stimulatory molecule used to generate the secondgeneration CARs is not limited to CD28. Song et al. and Homback et al. demonstrated
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that CD27 or 4-1BB (CD137) and OX40 (CD134) can also promote T cell proliferation
and improve CAR T cell function (26,27). The third-generation CARs are different in
that they are made by combining CD3ζ-CD28-OX40 or CD3ζ-CD28-41BB to enhance
the CARs' potential in terms of killing and cytokine secreting. This means that the thirdgeneration CARs have two co-stimulatory molecules rather than just one as in secondgeneration CARs (24).
The fourth-generation CARs, also known as TRUCKs (T cells redirected for antigen‐
unrestricted cytokine‐initiated killing), were generated by adding Interleukin 12 cytokine
(IL-12) to the base of the second-generation CARs. IL-12 cytokine produced by different
cells in response to an antigenic stimulation recruits macrophages that would destroy
bacteria or other harmful microorganisms. Thus, TRUCKs can also treat innate system
disorders such as viral infections. Studies exploring different cytokines such as IL-7, IL15, IL-18, and IL-23 to generate the fourth-generation CARs are still going on. Each has
different features, but all ultimately aim to enhance T cell functions (28). These
successive generations of CARs bring high expectations and hope in cancer treatment.
2.3 CAR T Cell Therapy Challenges
Over the decades, CAR T cell therapies have been under investigation due to their
unprecedented and unparalleled results in cancer treatments. Even though many
investigations aim to use CAR T cell therapies to treat different kinds of cancer, only a
few have been approved by Food and Drug Administration (FDA).
Clinical trials of CAR T cell therapies have shown remarkable results in B cell
malignancies. B cell malignancies include relapsed and refractory chronic lymphocytic
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leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL),
non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and acute
lymphocytic leukemia (ALL). B cell malignancy is a type of cancer formed in B cells.
This disease causes the formation of many abnormal B lymphocytes that cannot fight
germs as mature B cells do. B cells have a transmembrane glycoprotein, CD19, on their
cell surface from early pro-B development to the end of their differentiation into mature
B lymphocytes. B lymphocyte antigen CD19 is an attractive therapeutic target for CAR T
cell therapies to treat B cell lymphoma because its expression is restricted to B cell
lineage (29,30). Kochenderfer et al. treated a patient with advanced follicular lymphoma
with a combination of chemotherapy and genetically engineered T cell therapy. They
engineered T cells with retroviral vectors to express anti-CD19 CAR that was able to
recognize CD19. They reinfused those T cells into the body, and 64% of those expressed
the CAR as measured by flow cytometry. After nine weeks of the reinfusion, the patient's
lymphoma showed partial remission, and thirty-six weeks after anti-CD19 CAR
transduction, CD19+ cells were completely eradicated from their blood (31). After this
first effective CAR T cell therapy, Kochenderfer et al. reported on the first clinical trial
with 15 patients with DLBCL by using anti-CD19 CAR T cell therapy. Eight of the 15
patients showed complete remission, and four of them achieved partial remission. These
results demonstrated this treatment's broader effectiveness in treating B cell malignancies
(29,32).
Based on these successful results, many more studies have been conducted over the
years, and the first CAR T cell therapy Kymriah, marketed by Novartis, was approved by
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the FDA in 2017 for children and young adults up to age 25 with relapsed and refractory
(r/r) ALL, or for adults with r/r DLBCL (33,34). Before the approval of this therapy,
Maude et al. conducted Phase II ELIANA trial, the first pediatric global CAR T cell
therapy, with 63 pediatric and young adults with r/r ALL. Upon completing this study,
they found the overall remission rate as 83% within three months of infusion (35).
Another study conducted by Schuster et al. was the international Phase II JULIET trial,
the first multi-center global registration study, with 93 adult patients. The overall
response rate was 52%, including 40% of complete responses and 12% of partial
responses (36). One year after the approval, Kymriah was also authorized for use in
Europe (30).
Another CAR T cell therapy, Axicabtagene ciloleucel (AXI-CEL/KTE-C19),
marketed by Kite as Yescarta, received FDA approval in 2019 for patients with
aggressive r/r NHL including DLBCL. Locke et al. conducted phase I of the ZUMA-1
trial to support the KTE-C19 approval. Nine patients were enrolled in this study to
evaluate the safety and efficacy of anti-CD19 CAR T cells (37). After getting promising
results from this study, Neelapu et al. conducted phase II with 111 patients who have had
histologically large B cell lymphoma. Phase II of the ZUMA-1 trial showed an objective
response rate of 82% and a complete response of 54%. These results have made doctors
and scientists believe that Axicabtagene ciloleucel provides clinical benefits to patients
(38).
Despite the successful results for ALL patients, there are still challenges to overcome
for CAR T cell therapies. Today, two main challenges remain: selecting the right antigen
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to be targeted and ensuring T-cell migration to the solid tumor. An ideal antigen for solid
tumors should be highly expressed on them and remain unexpressed on other vital
tissues. As solid tumors' antigens may also be found on healthy tissues, it is very hard to
find the specific antigen for solid tumors (29,30).
Lack of a specific target antigen for solid tumors may cause on-target off-tumor
toxicity. This complication occurs when CAR T cells attack healthy cells that express the
intended target antigen. Although this toxicity may be clinically manageable and may not
be considered a life-threatening side effect for B cell malignancies, it is yet another
challenge for solid tumors (30). For instance, Morgan et al. discuss a case that came to a
catastrophic end. A 39-year-old female patient with metastatic colon cancer was infused
with the CAR T cells targeting HER2 (ERBB2) antigen, which is overexpressed in the
tumor microenvironment of some cancer types, including breast, colon, and ovarian
cancers. After the infusion, the patient's epithelial cells of the lung were attacked by the
CAR T cells, and she died five days after the infusion. Her death was attributed to the
low levels of HER2 in the epithelial cells (39). Since this fatal event, scientists have been
trying to find other cancer markers that are safer and more effective for solid tumors. One
such marker is ICAM-1 (intercellular adhesion molecule-1), and it bears CARs with
micromolar affinity rather than nanomolar affinity. Since ligands with nanomolar affinity
would bind more tightly to the proteins when compared to those of micromolar affinity,
ICAM-1 markers are expected not to bind to healthy cells tightly. The affinity of CARs
influences cytokine release. Thus, a reduced affinity targeting strategy would allow rapid
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tumor elimination while preventing the toxicity that would occur because of tight binding
(40).
The most frequently reported life-threatening toxicity associated with CAR T cell
therapy is cytokine release syndrome (CRS). After the infusion of CAR T cells into the
bloodstream, the number of cytokines, IFNγ, TNFα, and IL-2, in the body rises and
causes CRS. The symptoms of CRS include high fever, nausea, headache, and or mild to
severe tachycardia (30,41). Another CAR T cell-mediated fatal toxicity is neurotoxicity,
co-occurring or after CRS. Some common manifestations of neurotoxicity are headache,
confusion or delirium, and rarely acute cerebral edema (41,42). To date, both
neurotoxicity and CSR occur in many patients who are treated with CD-19 CAR T cell
therapy (30). Teachey et al. measured cytokine numbers in 51 patients’ bloodstream after
receiving CD-19 CAR T cell therapy for ALL. They realized a peak in the number of 24
cytokines including IFNγ and IL-6 (43). To identify risk factors of neurotoxicity resulting
from CD-19 CAR T cell therapy, Gust et al. studied 133 patients’ neurological adverse
events after the infusion. Fifty-three patients experienced neurological adverse events,
from mild symptoms to death. Also, the majority of the 53 patients had CRS as well.
These results led researchers to that CRS causes a higher risk of neurotoxicity
development (44).
2.4 Immunological Synapse
To activate the cell signaling pathway developed for this study, the formation of an
immunological synapse between the effector cells and the antigen-presenting cells
(APCs) is vital. An immunological synapse (IS) is a junction between APCs and
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lymphocytes, such as T cells, where the interaction of T cell receptors (TCRs) and
peptide major histocompatibility complexes (MHCs) occurs (46,47). IS is also known as
a supramolecular activation cluster (SMAC), and it is formed of three major
compartments: central SMAC (cSMAC), peripheral SMAC (pSMAC), and distal SMAC
(dSMAC) (46,48). The external ring, dSMAC, is composed of large membrane
glycoproteins such as CD43 and CD45 (48). It is the site where TCR microclusters (MC)
first engage with peptide-MHCs. Once TCR-MCs are formed, they are translocated
toward pSMAC, which is formed of integrins and the proteins involved in cell adhesion,
such as lymphocyte function-associated antigen-1 (LFA-1), the cytoskeletal protein talin,
and ICAM-1 (49,50). The inner circle, cSMAC, is the center area of this structure in
which TCRs, CD2, CD4, CD8, CD28, protein kinase Cθ (PKCθ), and lymphocytespecific protein tyrosine kinase (Lck) are concentrated (48,51). The proteins TCRs, CD2,
CD4, CD8, and CD28 are expressed on the surface of immune cells (such as T cells),
while Lck and PKCθ are expressed inside T cells. Whereas Lck associates with the
cytoplasmic tails of CD4 and CD8, PKCθ plays a key role in the T cell activation. Each
molecule mentioned here has an essential part in the function of IS, which integrates
antigens, adhesion molecules, and co-stimulatory molecules. The co-stimulatory
receptors CD4, CD8, and CD28 synergize to activate T cells, while the interaction
between LFA-1 on the T cell surface and ICAM-1 on APCs allows rapid T cell migration
and differentiation (46).
The formation of IS initiates the differentiation of naive T cells into effector T cells,
which defend the host against various pathogens and cancer cells (46,49). Upon the
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formation of IS, Lck phosphorylates and activates ZAP-70, a crucial protein kinase for
the three T cell signaling pathways. The first signaling pathway is NFAT (nuclear factor
of activated T cells), also known as the Calcium pathway. It can initiate gene expression
by itself or with other transcription factors (52). The second pathway, NFκB (nuclear
factor-κB), is essential for regulating immune responses and activates PKCθ, which is
vital for T cell activation (53,54). The third pathway is Activator protein 1 (AP-1), which
regulates gene expression, proliferation, differentiation, and even cell death (55). Though
each pathway has its essential role, their combined effect is necessary for T cells to
proliferate, differentiate, and have effector functions.
2.5 Chemokine System
Severe tissue damage occurs when immune cells migrate to the incorrect site and
attack healthy parts of the body. The chemokine system represents a potential target for
immunotherapy, and it is vital to prevent tissue damage. Besides their chemotactic
ability, chemokines can also regulate T cell development and their effector functions. The
four subfamilies of chemokines, differentiated by their initial cysteine residues position,
are CXC, CC, CX3C, and XC structural motifs (56,57,58). Chemokines exert their
biological effects by binding their corresponding G protein-coupled chemokine receptors.
Chemokines are secreted in the tumor microenvironment, and their cognate receptors are
expressed by tumor cells. There are almost 50 distinct chemokines and 20 chemokine
receptors identified in humans. Some chemokine receptors are specific to one chemokine,
and others may bind to many (58). Table 1 shows chemokines (ligands) and their
corresponding receptors (59).
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Table 1. Chemokines and Corresponding Chemokine Receptors
Chemokine

Ligand

Receptor

CCR1

CCL3, CCL4, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16,
CCL23

CCR2

CCL2, CCL7, CCL8, CCL12, CCL13, CCL16

CCR3

CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24,
CCL26, CCL28

CCR4

CCL2, CCL3, CCL5, CCL7, CCL22

CCR5

CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16

CCR6

CCL20

CCR7

CCL19, CCL21

CCR8

CCL1, CCL4, CCL17

CCR9

CCL25

CCR10

CCL27, CCL28

CXCR1

CXCL6, CXCL8
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CXCR2

CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8

CXCR3

CXCL9, CXCL10, CXCL11

CXCR4

CXCL12

CXCR5

CXCL13

CXCR6

CXCL16

CXCR7

CXCL11, CXCL12

CX3CR1

CX3CL1

XCR1

XCL1, XCL2

In terms of the chemokines’ function, there are two subfamilies, homeostatic and
inflammatory chemokines. Homeostatic chemokines mainly direct the flow of leukocyte
traffic throughout the body to screen for an invasion of pathogens. This family includes,
but is not limited to, CCL14, CCL19, CCL20, CCL21, CCL25, CCL27, CXCL12, and
CXCL13 (57). In different parts of the body, different chemokines recruit immune cells.
For instance, CCL27 recruits T leukocytes in the skin, and CXCL12 mediates leukocytes
homing in the brain (59). Some chemokines promote the formation of new blood vessels
(angiogenesis). Although it is a part of the healing and growth of tissues, angiogenesis
inhibitors can be essential for several diseases, including cancer. Since tumor cells need
oxygen and nutrients to grow and spread to the other parts of the body, angiogenesis
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inhibitors could block them from going to tumor cells. As a result, tumor cells starve and
cannot grow or spread (60). Another chemokine family, inflammatory chemokines, is
secreted to infection, tissue injury, or tumors. They control the inflammatory response of
immune cells to infectious sites. CXCL8, CCL2, CCL3, CCL4, CCL5, CCL11, and
CXCL10 are examples of inflammatory chemokines (61). However, these classifications
are flexible, and some homeostatic chemokines may also be considered part of the
inflammatory chemokines’ family (62).
As one aim of this study was to have effector cells migrate to the tumor
microenvironment directly, target and effector cells were engineered to express
chemokines and their respective corresponding receptors. Chemokines and their
corresponding receptors tend to bind each other. As a result, effector cells engineered to
express chemokine receptors should be expected to go directly to the tumor
microenvironment where the corresponding chemokines are secreted. Chemokines that
are secreted in the tumor microenvironment depend on the type of cancer.
2.6 Gene Therapies
Genes maintain the production of proteins and enzymes within cells, providing
essential body functions. Gene therapies to treat or prevent diseases have been
investigated by scientists for decades. Gene therapy is the introduction of genomic
material into a specific cell to give it new functions or the introduction of genomic
material into a defective cell to correct abnormalities. There are many aspects of
successful gene therapy, such as an effective therapeutic gene or an animal model
simulating disease.
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Gene therapy is divided into two categories: somatic gene therapy and germline gene
therapy. Some consider germline therapy to be unethical as it replaces an offspring’s
defective genes with healthier ones and is used to treat genetic disorders. It is
controversial because it changes someone’s genetics who is not yet born, so they do not
say whether they want treatment (63,64). Somatic gene therapy is considered to be
ethically safer, as it affects only the patients’ genes, not future generations. There have
been two delivery techniques for somatic gene therapy, viral and non-viral. Both delivery
techniques have one goal: delivering genetic material across cell membranes and
reaching the cell’s nucleus (63).
In the 1990s, the potential of gene therapy created excitement, and many studies were
conducted. However, the lack of experience in the clinical applications of viral vectors
and their safety issues caused two catastrophic events. In 2003, Raper et al. reported the
death of an 18-year-old male with partial ornithine transcarbamylase (OTC) deficiency,
which is not a life-threatening disease. Adenovirus type 5 was used to deliver the gene
therapy, and he was the 18th subject who received it. Before him, no one showed the
symptoms he showed. Approximately 18 hours after the delivery, he reported not feeling
well and died. His death was attributed to systemic inflammatory response syndrome and
multiple organ system failures. After this experience, animal studies’ limitations in
predicting human responses and subject-to-subject symptom variations were determined
(65,66). Although the unsuccessful results led to a decrease in funding for gene delivery,
there were, and still are, many scientists who believed in it. With this, gene delivery has
become one of today’s promising therapies.
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Viral gene delivery uses viruses to deliver genetic material; the viruses include
adenoviruses, gamma retroviruses, lentiviruses, and adeno-associated viruses.
Lentiviruses are a subclass of retroviruses. They have been used widely in scientific
research as they have unique features, including the ability to integrate with both nondividing and dividing cells. Lentiviral vectors are derived from human immunodeficiency
virus type 1 (HIV-1), becoming nonpathogenic and safe to use after some modifications
(67). Naldini et al. proved that lentiviral vectors can be used in in vivo gene therapy in
non-dividing cells, and they predicted that their feasibility in human gene therapy would
improve (68). Lamers et al. conducted a study using gamma retroviruses instead, using γretroviruses to modify the genes ex vivo of patients with metastatic renal cell carcinoma.
In some patients, immunity against γ-retroviral vectors occurred, concerning researchers
about γ-retroviral ex vivo applications (69). Different viral vectors have their advantages
and disadvantages, and the selection should be specific to the study. In this study,
lentiviruses were used to transfer the intended genetic materials to cells due to the
advantages mentioned above.
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3 Research Hypotheses
3.1 Specific Aim 1: Developing a K562 Biofactory to Synthesize Therapeutic
Proteins
In this study, to find a cheaper alternative to CAR T cell therapies, K562 cells were
explored as a biological chassis to evaluate their ability to synthesize engineered
therapeutic proteins when engaged with ovarian cancer cells. In this part of the study,
K562 cells were engineered with an artificial cell-signaling pathway whose design
transforms them into antigen-specific effector cells producing Nanoluc luciferase
enzyme, a quantifiable non-human effector protein. This pathway contained three
constants (receptor, actuator, secretor) and two variable (sensor, effector) domains.
Whereas the constant domains gave biofactory functionality, the variable domains
expanded the possibility of targeting different cell-based diseases.
The artificial cell signaling pathway developed here was a third-generation CAR. It
was developed to be activated by an immunological synapse, which was to be formed
between K562 cells and ovarian cancer cells when they engage with one another. When
the pathway was activated, it was expected K562 cells synthesize the Nanoluc luciferase
enzyme. In order to have quantifiable results and demonstrate if this system has worked,
a NanoGlo luciferase assay system was used to measure the production of Nanoluc
luciferase reporter. The null hypothesis was that K562 can be used as a cellular chassis
for developing a biofactory technology as an alternative to T cells in the treatment of
ovarian cancer, and the alternate hypothesis was the other way around.
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3.2 Specific Aim 2: Engineering Jurkat Cells with Chemokine Receptors to Evaluate
Their Migration Towards the Ovarian Cancer Microenvironment and Their
Cytotoxic Functions on Tumor Cells
In the second part of the study, the aim was to prevent tissue damage on healthy areas
of the body and to see the cytotoxic functions of Jurkat cells on tumor cells. In order to
have Jurkat cells migrate directly towards the tumor microenvironment, they were
engineered to express two chemokine receptors independently. When chemokine
receptors interact with chemokines, they tend to bind to corresponding ligands. For this
study, appropriate chemokine receptors were expected to be highly expressed on
cytotoxic T cells (CD8+ T cells) and helper T cells (CD4+ T cells). Also, their low
expression on T regulatory cells was another consideration. The reason was that Treg
cells, also known as suppressor T cells, regulate and suppress other immune cells’
functions. So, their activation could prevent the migration of cytotoxic T cells into the
tumor microenvironment. The chemokine receptors selected here were CCR5 and CCR7
due to the reasons mentioned above. Whereas Jurkat cells were engineered to express
CCR5 and CCR7, ovarian cancer cells were engineered to express CCL5 and CCL19, the
corresponding ligands of CCR5 and CCR7. As a result, it was expected that CCR5 and
CCR7 chemokine receptors of Jurkat cells would migrate directly towards the
corresponding ligands and bind to them.
On the other hand, to give cytotoxic functions to Jurkat cells, they were modified to
express CAR on their cell surface. Jurkat cells were also modified with anti-folate
receptor alpha to recognize folate receptor alpha, a receptor highly expressed on ovarian
cancer cells’ surface. The last modification done was the engineering of Jurkat cells with
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luciferase enzyme to give them quantifiable features. Here again, a NanoGlo luciferase
assay system was used to obtain measurements.
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4 Materials and Methods
In this part, the materials and methods used to test the hypotheses for the two specific
aims are discussed.
4.1 Specific Aim 1
To test the hypothesis of the specific aim 1, Jurkat and K562 biofactories were
developed by designing an artificial cell-signaling pathway. As mentioned earlier, this

pathway included five domains: the receptor, the actuator, the secretor, the sensor, and
the effector. The receptor part was generated by adding an activator motif, CD3ζ, and costimulatory molecules, 4-1BB and CD28. The CAR generated here was the third

generation. Whereas CD3ζ led to a rise in the intracellular calcium (Ca2+) concentration,
the combination of 4-1BB and CD28 enhanced the therapeutic response of CAR T cells.
The actuator part was based on six copies of NFAT-RE (NFAT-RE6X, nuclear factor of

activated T cell response) that would respond to Ca2+ rise and upregulate luciferase
activity. The secretor part was composed of human interferon alpha-2 (IFN-2) that
activates T cells to fight cancer cells and inhibits tumor cells’ proliferation. The other two
parts, the sensor, and the effector, were subject to change depending on the study. In this
case, the sensor part was developed to detect folate receptor alpha (FR), which is a
receptor found on the surface of many cancer cells including ovarian cancer cells. Two
different ovarian cancer cell lines (OVCAR-3 and A2780cis) were used in this study.
OVCAR-3 human ovarian cancer cells were used as target cells because they express
FR and can be detected by the anti-folate receptor alpha on the biofactory cells’ surface.
On the other hand, A2780cis human ovarian cancer cells lacking FR were used as non-
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target negative controls. The fifth part of the pathway, an effector part, may comprise
different reporter transgenes. In this study, a quantifiable non-human effector protein,
Nanoluc luciferase reporter, was used for proof-of-concept. If biofactories can produce
Nanoluc enzyme, they can be manipulated with different therapeutic proteins, instead of a
quantifiable non-human protein, to give them therapeutic functions.
To generate Jurkat and K562 biofactories, lentiviruses, with the necessary genetic
material mentioned earlier, were produced by the transfection of HEK293T/17 cells.
Once lentiviruses were generated, Jurkat and K562 parental cell lines were transduced
with these viruses. To check if the transduction was successful, engineered cells'

live/dead status was compared to one of the positive control cells (parental cell lines).
Both transduced and unmodified cells were placed under selection for two weeks with
puromycin, a type of antibiotic used to select and maintain cells stably transfected with

viral vectors expressing puromycin. It was expected that successfully engineered cells
stay alive under the selection. Once alive engineered cells were selected and grown in the
laboratory, they were co-cultured with target and non-target cancer cells. The Nanoluc

activity of cell biofactories was measured with a microplate reader called NanoGlo
Assay. Three 96-well plates were seeded with different co-culture combinations to
measure the Nanoluc activity produced by Jurkat and K562 biofactories when they
engaged the target and non-target cells in respect to 24hr, 48hr, and 72hr. Figure 1
illustrates the type of seeded cells in the plates.
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Jurkat Biofactory and OVCAR-3
Jurkat Biofactory and A2780cis
K562 Biofactory and OVCAR-3
K562 Biofactory and A2780cis
Jurkat Biofactory cells
K562 Biofactory cells
OVCAR-3 cells
A2780cis cells
Figure 1. The combination of seeded cells in the 96-well plates
To understand the effect of cancer cells’ mass on the Nanoluc synthesis, another
NanoGlo assay was applied with the cell combinations shown in Figure 1. In this
experiment, effector cell numbers remained constant, and target cell numbers were

serially diluted. Nanoluc activity of biofactories was measured at 24 hours of co-culture.
4.1.1 Materials and Reagents
K562-BF, Jurkat-BF, OVCAR-3 (ATCC), and A2780cis (ATCC) cell lines were

maintained in complete RPMI media [RPMI1640 with L-glutamine (Corning, CAT#
10-040CV), and 10% fetal bovine serum (Sigma-Aldrich, Cat# F2442-500ml)].
Puromycin dihydrochloride (Thermo Fisher Scientific, Cat# A1113803) was used for

selecting engineered cells.
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4.1.2 Reviving Cell Lines
Already engineered K562-BF and Jurkat-BF cell lines were provided by Dr. Parijat
Bhatnagar’s laboratory. All frozen cells were rapidly (< 2 minute) thawed in a 37°C
water bath. Thawed cells were slowly diluted with 10ml of pre-warmth complete RPMI
media in a Falcon 15 mL conical centrifuge tube. Then, 15 mL tube was vortexed and
centrifuged at 200G for 8 minutes. After the supernatant was removed, cells were
resuspended with 5ml of growth media. After 48 hours of revival, K562-BF and JurkatBF were placed in selection using 0.5 µg mL-1 and 0.2 µg mL-1 of puromycin
dihydrochloride respectively for two weeks. After selection, all cell line were expanded

for NanoGlo Assays and then were frozen using freezing media (complete culture media
and 10% DMSO) for liquid nitrogen stocks.
4.1.3 Stimulation of Biofactories

2500 cells of OVCAR-3 and A2780cis were co-cultured with 12500 cells of JurkatBF and K562-BF in 100 µL of complete RPMI media in a single well of 96-well plate.
Also, OVCAR-3, A2780cis, Jurkat-BF and K562-BF were also seeded as controls, which
were to be chemically stimulated with PMA ionomycin to evaluate the function of
biofactories. Three 96-well plate were seeded for three time points (24, 48, and 72 hours).
4.1.4 Stimulation of Biofactories with Variant Target Cells’ Mass
12500 cells of Jurkat-BF and K562-BF were co-cultured with variant target and nontarget cell numbers (from 125000 to 976) in 100 µL of complete RPMI media in a 96well plate. Cell number variation was obtained by serially diluting downwards of target
cells.
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4.1.5 NanoGlo Assay to Measure Nanoluc Activity
Nanoluc substrate was diluted in the cell lysis buffer, which was provided with the
NanoGlo assay. It was added 1:1 to cells. After 3 minutes of incubation, Nanoluc activity
of biofactory cells was read on a microplate reader (Perkin Elmer, Envision Multilabel
Plate Reader Model: 2104-0010A).
4.2 Specific Aim 2

In this part of the study, the aim was to have effector cells, Jurkat cells, migrate
towards the ovarian cancer cells, OVCAR-3 cells. Jurkat parental cells were manipulated
with lentiviruses to recognize FR on OVCAR-3 cells’ surface. Also, they were

engineered, independently, to express CCR5 and CCR7 chemokine receptors, and not to
express CCR5 and CCR7. The cells engineered with CCR5 and CCR7 expressed these
chemokine receptors on their cell surfaces. On the other hand, the cells engineered with

CCR5 endogenous shRNA and CCR7 endogenous shRNA did not express these
receptors. shRNA molecules knocked down gene expression. To check their chemotactic
ability Jurkat cells were co-cultured with OVCAR-3 cells (target cells), which were
engineered to express CCL5+, CCL5-, CCL19+, and CCL19-, the corresponding ligands of
CCR5+, CCR5-, CCR7+, and CCR7-. Figure 2 illustrates different combinations of
chemokine receptors expressed by Jurkat cells and chemokines secreted in the ovarian
tumor microenvironment.
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CCR5- and CCL5CCR5+ and CCL5CCR5- and CCL5+
CCR5+ and CCL5+
CCR7- and CCL19CCR7+ and CCL19CCR7- and CCL19+
CCR7+ and CCL19+

Figure 2. Combinations of chemokines and their receptors
4.2.1 Materials and Reagents
Parental Jurkat and OVCAR-3 cells (ATCC) were maintained in complete RPMI
media [RPMI1640 with L-glutamine (Corning, CAT# 10-040CV), and 10% fetal bovine
serum (Sigma-Aldrich, Cat# F2442-500ml)] to be engineered. HEK293T/17 cells were
maintained in complete DMEM media [DMEM with L-glutamine and 10% fetal bovine
serum) to produce lentiviruses. Puromycin dihydrochloride (Thermo Fisher Scientific,
Cat# A1113803) or G418 (Corning, Cat# 30 234-CR) was used for selecting engineered
cells.
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4.2.2 Lentivirus Production
HEK293T/17 cells were seeded and maintained in complete DMEM. In a 1.5mL
microtube, 150mM NaCl, pAdv, pMD2.G, psPAX2, transporter, and the corresponding
transfer plasmid [LentiStarter 2.0 kit (System Biosciences)] were mixed. This mixture
was added on the plated HEK293T/17. Viral supernatant was collected 24, 48, and 72
hours after transfection. Viral supernatant was filtered and ultracentrifuged by using
Polypropylene Konical ultracentrifugation tube (Beckman Coulter #C14291) in Beckman
Coulter ultracentrifuge (Beckman Coulter #369650).
4.2.3 Transduction of Parental Cell Lines

Corresponding lentivirus particles were added to parental cell lines (Jurkat and
OVCAR-3). After five hours of incubation, polybrene was added to flasks.
4.2.4 Boyden Chamber Assay
Respective OVCAR-3 cells engineered with ligands were seeded at 10000 per well
in a 24-well plate. After 24 hours of incubation, respective Jurkat cells engineered with
chemokine receptors were seeded at 1x106 per well in Boyden chambers. Boyden
chamber assemblies were incubated for 3 and 6 hours, and Boyden chambers were
discarded. Migrated Jurkat cells were allowed to be co-cultured with OVCAR-3 cells for
48 hours.
4.2.5 NanoGlo Assay to Measure Luciferase Activity
Luciferase reagent was added to each well of 24-well plate and plates were incubated
for 5 minutes. Cells in 24-well plate were transferred to 96-well plate to be read
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luminescence on a microplate reader (Perkin Elmer, Envision Multilabel Plate Reader
Model: 2104-0010A).
The most important safety consideration for Specific Aim 1 and 2 was to work with
lentiviral vectors. While working with viruses, double gloves, double lab coats, and lab
goggles must be worn. Also, ten percent of bleach must be always found in the hood to
remove used pipettes.
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5 Results
In this thesis, two hypotheses were evaluated to be true or false through the data
obtained by various experiments explained above. The first hypothesis was that K562
cells could be used as a cellular chassis for developing a biofactory technology to
produce therapeutic proteins for targeting diseased cells. In the first part (Figure 3, Figure
4, Figure 5), the hypothesis that K562 cells synthesize engineered proteins in situ upon
the interaction with ovarian cancer cells was evaluated. In the second part of the study
(Figure 6, Figure 7), the hypothesis that manipulated Jurkat cells migrate towards ovarian
cancer cells and have a cytotoxic effect on them was evaluated. For all comparisons of
statistical significance, two-sample t-tests with common variance were used. Values of P
< 0.05, P < 0.01, and P < 0.001 were considered as being significant, very significant, and
extremely significant respectively. Values of P > 0.05 were considered as being not
significant. The results are expressed as mean (M) ± standard deviation (SD).
5.1 Specific Aim 1. K562 Biofactory Function
5.1.1 NanoLuc Luciferase Expression Measurement of Chemically Stimulated
Biofactories
First, the function of K562 and Jurkat cell biofactories that had been chemically
stimulated with Phorbol 12-Myristate 13-Acetate (PMA) ionomycin formulation were
tested to see whether the cells were engineered successfully, and they were able to
synthesize the NanoLuc enzyme. The comparison between chemically stimulated and
non-stimulated biofactories is shown below (Figure 3).
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Figure 3. Demonstration of chemically stimulated K562 and Jurkat cells biofactories’
function. Chemically stimulated and non-stimulated effector cells from both biofactories
were compared to each other. 50,000 cells were seeded for each condition. Statistics
between K562 and Jurkat biofactories were calculated by a two-sample t-test assuming
equal variances. Values are expressed as mean ± SD. P values: *P < 0.05, **P < 0.01,
***P < 0.001. a.u., arbitrary unit.
Nanoluc activity of chemically stimulated and non-stimulated Jurkat biofactories
(Jurkat-BF) was measured as 82 x 106 a.u. ± 1.4 x 106 and 2.4 x 106 a.u. ± 0.11 x 106;
Nanoluc activity of chemically stimulated and non-stimulated K562 biofactories (K562BF) was measured as 57.4 x 106 a.u. ± 4.7 x 106 and 0.421 x 106 a.u. ± 0.064 x 106.
Statistical analysis supported that the difference between the amount of Nanoluc
synthesized by chemically stimulated and non-stimulated biofactories was extremely
significant (p = 7.17x10-18 for Jurkat-BF and p = 4.32x10-11 for K562-BF), meaning
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chemically stimulated biofactories were able to produce a significant amount of Nanoluc
compared to a non-stimulated biofactory.
5.1.2 NanoLuc Luciferase Expression Measurement of Biofactories that Interact with
Cancer Cells
Second, to evaluate the K562 biofactory function in situ upon interaction with ovarian
cancer cells, Nanoluc expression of effector cells (K562-BF and Jurkat-BF) and target
cells (OVCAR-3 and A2780cis cells) co-cultures were measured and compared to each
other. Co-culture of effector cells with OVCAR-3 cells were used as positive controls,
and co-culture of effector cells with A2780cis cells were used as negative controls.
It was expected that both biofactories would produce the Nanoluc enzyme when
engaged with OVCAR-3 cells. The Nanoluc amount expressed by K562-BF was
compared to the one expressed by Jurkat-BF to evaluate whether K562 cells could be
substituted for T cells as a cellular chassis for developing a biofactory technology.
The chemically stimulated biofactories were able to synthesize the Nanoluc enzyme
whereas chemically stimulated target cells were not (Figure 3). When the Nanoluc
expression of the positive control and negative control of Jurkat-BF (13.43 x 106 a.u. ±
1.3 x 106 and 0.95 x 106 a.u. ± 0.13 x 106) were compared to each other, it was seen that
Jurkat cells synthesize Nanoluc in situ upon interaction with OVCAR-3 cells. This
finding was also supported by a two-tail t-test (p = 0.008). It was concluded that the
difference between co-cultures of Jurkat-BF with positive and negative controls was very
significant. However, the co-cultures of K562-BF with OVCAR-3 and A2780cis (0.21 x
106 a.u. ± 0.014 x 106 and 0.17 x 106 a.u. ± 0.035 x 106) expressed almost the same
amount of Nanoluc enzyme (p = 0.46), meaning K562-BF did not produce Nanoluc when
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engaged with antigen-presenting target cells. To confirm this finding, a two-tailed t-test
between co-cultures of biofactories with OVCAR-3 was applied and again K562-BF did
not produce Nanoluc enzyme as Jurkat-BF did (p = 0.007, a very significant difference).
All t-tests were done according to the data at 48 hours (Figure 4).
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JK-BF
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Figure 4. Nanoluc expression measurement of effector cells, JURKAT-BF and K562-BF,
after co-culture with target cells, OVCAR-3 and A2780cis, and of chemically stimulated
(PMA ionomycin) K562-BF, JURKAT-BF, OVCAR-3, and A2780cis cells at 24, 48, and
72 hours. 12,500 effector and 2,500 target cells were seeded for each condition. Statistics
were calculated by a two-sample t-test assuming equal variances. Values are expressed as
mean ± SD. P values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit.
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5.1.3 Effect of Target Cells’ Mass on Nanoluc Enzyme Expression
Last, we tested the effect of target cells’ mass (OVCAR-3 and A2780cis) on Nanoluc
enzyme synthesis by the biofactories. Eight different amount of target cells (from
125,000 to 976 cells) were co-cultured with same amount of effector cells. For Jurkat-BF,
effector protein activity was proportional to the mass of target cells. However, for K562BF, the mass of target cells did not have any effect on the Nanoluc expression as K562BF cells were almost unable to produce Nanoluc enzyme when encountered by the
antigen presenting target cells (Figure 5). This finding was supported by statistical
analysis done between the co-cultures of biofactories with OVCAR-3 cells, where the
number of seeded cells of effector and target cells were 12,500 and 125,000 respectively.
It was concluded that K562-BF did not produce Nanoluc as Jurkat-BF did, and there was
an extremely significant difference between their Nanoluc expression

Nluc activity after 24
hours co-culture (x10^6)
(a.u.)

(p = 2.9 x 10-6).
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K562-BF / OVCAR3

K562-BF / A2780
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Figure 5. Evaluation of the effect of target cells’ mass on the effector cells’ Nanoluc
expression. Target cell numbers were serially diluted from 125,000 to 976 cells whereas
effector cell numbers remained constant at 12,500 cells. Statistics were calculated by a
two-sample t-test assuming equal variances. Values are expressed as mean ± SD. P
values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit.
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5.2 Specific Aim 2. Function of CAR Jurkat Cells Engineered with Chemokine
Receptors
In this part of the study, the migration and cytotoxic ability of Jurkat cells on
OVCAR-3 cells were tested. Results were found by measuring luciferase (Luc2)
expression of cancer cells.
5.2.1 Function of CCR5 Jurkat Cells
First, we tested the killing ability of Fr-CAR Jurkat cells expressing CCR5 on
OVCAR-3 cells. Various statistical analyses were applied with different co-cultures
combinations illustrated in Figure 2. Fr-CAR Jurkat cells expressing CCR5 chemokine
receptor (Jurkat CCR5+) were co-cultured with OVCAR-3 expressing CCL5 (OVCAR-3
CCL5+) and OVCAR-3 non-expressing CCL5 (OVCAR-3 CCL5-). Fr-CAR Jurkat nonexpressing CCR5 (Jurkat CCR5-) was also co-cultured with OVCAR-3 CCL5+. Then, the
migration and cytotoxic ability of Fr-CAR Jurkat cells on OVCAR-3 cells were
measured at 3 and 6 hours. Luc2 expression of OVCAR-3 cells are illustrated below
(Figure 6).
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Figure 6. The migration ability and cytotoxic effect of CAR Jurkat CCR5+ and CAR
Jurkat CCR5- on OVCAR-3 CCL5+ and OVCAR-3 CCL5- are shown by the
measurement of Luc2 expression of target cells. Luc2 expression of OVCAR-3 CCL5cells co-cultured with CAR Jurkat CCR5+ and CAR Jurkat CCR5- were measured as
12356 a.u. and 9329 a.u. at 3 hours, and 20516 a.u. and 14849 a.u at 6 hours respectively.
Luc2 expression of OVCAR-3 CCL5+ cells co-cultured with CAR Jurkat CCR5+ was
measured as 2604 a.u. at 3 hours and 2498 a.u. at 6 hours. OVCAR-3 cells and CAR
Jurkat cells were seeded at 10,000 and 1x106 cells for each condition. Statistics were
calculated by a two-sample t-test assuming equal variances. Values are expressed as
mean ± SD. P values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit.
It was hypothesized that Jurkat CCR5+ cells would migrate more towards OVCAR-3
CCL5+ cells and have a higher cytotoxic effect on them compared to their co-culture with
OVCAR-3 CCL5- cells after both 3 and 6 hours. This hypothesis was proven by
statistical analyses done between Jurkat CCR5 + / OVCAR-3 CCL5- and Jurkat CCR5+ /
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OVCAR-3 CCL5+ at 3 and 6 hours (p = 0.027 at 3 hours and p = 6x10-5 at 6 hours).
Another analysis was done between 3 and 6 hours to understand whether time has an
effect on the migration and killing ability of Jurkat cells. It was found that the cytolytic
ability of Jurkat CCR5+ cells on OVCAR-3 CCL5+ cells remained constant after 3 and 6
hours co-culture (p = 0.79, no significant difference).
The second hypothesis was that Fr-CAR Jurkat CCR5+ cells would migrate more
towards OVCAR-3 CCL5+ cells and have more killing effect on them than the migration
and killing ability of Jurkat CCR5- cells on OVCAR-3 CCL5- cells. This hypothesis was
supported by the statistical analysis done between Jurkat CCR5+ / OVCAR-3 CCL5+ and
Jurkat CCR5- / OVCAR-3 CCL5- at both 3 and 6 hours. At 3 hours the difference was
very significant (p = 0.0034) and at 6 hours the difference was extremely significant
(p = 6x10-7).
5.2.2 Function of Jurkat Cells Expressing CCR7+ and CCR7Second, we tested the migration and killing ability of Fr-CAR Jurkat cells
expressing CCR7 on OVCAR-3 cells. The hypothesis for this stage of the study remained
the same as the previous stage, which Fr-CAR Jurkat CCR7+ cells would migrate more
towards OVCAR-3 CCL19+ cells and would have a higher cytotoxic effect on them
compared to their co-culture with OVCAR-3 CCL19- cells. Luc2 expression of
OVCAR-3 cells are demonstrated below (Figure 7).

40

Luc2 Activity after 3 and 6 hours co-culture (a.u)

***
***
***
***

40000
35000
30000
25000
20000
p = 0.058
15000
10000
5000
0
CCR7- / CCL19-

CCR7+ / CCL193hr
6hr

CCR7+ / CCL19+

Figure 7. The migration ability and cytotoxic effect of CAR Jurkat CCR7+ and CAR
Jurkat CCR7- on OVCAR-3 CCL19+ and OVCAR-3 CCL19- are shown by the
measurement of Luc2 expression of target cells. Luc2 expression of OVCAR-3 CCL19cells co-cultured with CAR Jurkat CCR7+ and CAR Jurkat CCR7- were measured as
26871 a.u. and 16267 a.u. at 3 hours, and 32467 a.u. and 16293 a.u. at 6 hours
respectively. Luc2 expression of OVCAR-3 CCL19+ cells co-cultured with CAR Jurkat
CCR7+ was measured as 4627 a.u. at 3 hours and 3760 a.u. at 6 hours. OVCAR-3 cells
and CAR Jurkat cells were seeded at 10,000 and 1x106 cells for each condition. Statistics
were calculated by two-sample t-test assuming equal variances. Values are expressed as
mean ± SD. P values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit.
The Fr-CAR Jurkat CCR7+ cells migrated more to OVCAR-3 CCL19+ than
OVCAR-3 CCL19- at both 3 and 6 hours. The difference at both 3 and 6 hours was
extremely significant (p = 0.00014 and p = 3.8x10-5). The cells’ killing ability at 3 and 6
hours was same (p = 0.058, no significant difference). It was also found that Jurkat
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CCR7+ cells’ killing ability on OVCAR-3 CCL19+ was much higher than Jurkat CCR7cells on OVCAR-3 CCL19-. The difference between their cytolytic effect at 3 and 6
hours was extremely significant (p = 0.00037 at 3 hours and p = 0.00012 at 6 hours).
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6 Discussion
Despite having unprecedented and unparalleled results in cancer treatments, CAR T
cell therapies are not affordable for many patients and may have fatal side effects. Thus,
Bhatnagar et al. studied T cell biofactory technology (45) and transformed T cells into
living vectors to synthesize therapeutic proteins in situ when engaging with diseased cells
in the body. Yet, this technology is very expensive and may have side effects as it uses
Jurkat cells, an immortalized line of human T lymphocytes cells. This thesis aimed to
create a cheaper and safer alternative to CAR T cell therapy by testing the hypothesis that
K562 cells can be used as a cellular chassis to synthesize therapeutic proteins when
encountering diseased cells. K562 cells used in this research were derived from a 53year-old woman with chronic myelogenous leukemia in blastic crisis, and they can be
easily manipulated and keep the expression of manipulated genes stable (70).
To evaluate the hypothesis, this study was divided into two parts. The first part
investigated whether K562 cells would synthesize the engineered protein, Nanoluc
luciferase, when interacting with antigen-presenting cells. The second part evaluated
whether engineered Jurkat cells migrate to target cells with the help of chemokine
receptors and if they have a cytolytic effect on them. If promising results from the second
part were found, the same system could be implemented in K562 biofactories in later
studies.
6.1 K562 Biofactory Function Evaluation
A brief ex-vivo stimulation of Jurkat and K562 biofactories was conducted using
PMA ionomycin. PMA ionomycin formulation activates multiple intracellular signaling
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pathways, resulting in the biofactories’ activation. While there are other methods to
stimulate cytokine production, the optimal method is to use this formulation, as found by
Ai et al. in 2013 (71).
PMA activates protein kinase C (PKC), which has an essential role in mature T cell
activation. When immune cells are engaged with antigens of cancer cells in normal
conditions, CD3ζ, a part of CAR signaling, causes Ca2+ to rise within the cells. PKC
enzymes are in turn activated by these signals. Consequently, T cells are activated.
Alternately, ionomycin is a calcium ionophore that facilitates the calcium ion transfer
into and out of cells. When ionomycin is combined with PMA, they activate NFκB and
NFAT transcription factors, leading to cytokine production (72).
As previously mentioned in Materials and Methods for Specific Aim 1, the artificial
cell-signaling pathway of both biofactories was composed of three constant domains
(receptor, actuator, secretor) and two variable domains (sensor, effector). The receptor
domain consisted of the CD3ζ signaling domain (causing Ca2+ to increase upon
interaction with antigen-presenting cells), the CD28 that connects the intracellular and
extracellular domains of CAR, and 4-1BB that enhances the therapeutic response of
CAR. The actuator domain contained six copies of NFAT-RE (NFAT-RE6X), and IFN
alpha-2 was selected as a secretor due to its high Nanoluc activity. Bhatnagar et al.
evaluated three versions of the actuator domain (three, six, and nine copies of NFATRE), and five different signal peptides for the secretor domain (HSA, IL-6, IL-2, Gluc,
and IFN alpha-2) (45). Specific to this study, the sensor part was derived from an anti-
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Fr antibody to detect Fr receptor on target cells. The Nanoluc reporter enzyme was
used as an effector.
As both biofactories were engineered with identical constant and variable domains,
their structure was expected to be the same. Thus, it was anticipated that PMA ionomycin
would activate them both. From the comparison of the Nanoluc expression by chemically
stimulated and non-stimulated biofactories, it was concluded that biofactories activated
by PMA ionomycin were able to synthesize Nanoluc whereas non-stimulated ones were
not (Figure 3). This meant the engineering of K562 and Jurkat cells was successful, and
the cells were ready to be co-cultured with antigen-presenting target cells and non-target
cells to evaluate their function of Nanoluc synthesis in situ upon engaging with cancer
cells.
The feasibility of the K562 cell biofactory’s engineered protein synthesis for targeting
diseased cells was compared to the Jurkat biofactory, the feasibility of which was already
proven in situ upon engaging with ovarian cancer cells (45). Both biofactories were
engineered to recognize a specific receptor on the cancer cells’ surface, facilitating their
protein expression after stimulation.
Two different ovarian cancer cell lines were used to prove the function of
biofactories. The rationale behind the selection of two distinct ovarian cancer cell lines
was the expression of a specific receptor, Fr. Fr is overexpressed on OVCAR-3 cells,
and its expression on normal cells is limited (45, 73). Thus, OVCAR-3 cells were used as
target cells (positive controls) as Fr would enable ligand-receptor recognition between
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cancer cells and biofactories. A2780cis cells lacking Fr were used as non-target
negative controls.
Upon engaging target cells and biofactories, it was expected that Fr on Jurkat-BF
and K562-BF would engage the antigens on target diseased cells, which would, in turn,
result in biofactory activation. Along with this activation, Nanoluc and IFN-2 syntheses
were upregulated. IFN-2 (secretor peptide) was cleaved off, and Nanoluc (effector
peptide) was transported in the extracellular space (45).
The results obtained from the co-culture of Jurkat-BF, with positive and negative
controls, demonstrated that Fr found on the surface of OVCAR-3 cells enabled JurkatBF’s stimulation and thus synthesized the Nanoluc reporter enzyme. Nanoluc enzyme,
which produces bright and sustained luminescence (74), represented a quantifiable nonhuman effector protein. The Nanoluc expressed by Jurkat-BF co-cultured with OVCAR-3
cells was much greater than the Jurkat-BF and A2780cis co-culture at 24, 48, and 72
hours (Figure 4). The findings of Bhatnagar et al. (45), a similar study, support these
results.
Even though both Jurkat and K562 cells were engineered with the same artificial cellsignaling pathway, co-cultured K562-BF and OVCAR-3 did not elicit similar results to
the co-cultured Jurkat-BF and OVCAR-3. The results of the chemically stimulated K562
cells’ expression of the Nanoluc enzyme showed that they were successfully stimulated
by PMA ionomycin and synthesized the Nanoluc enzyme. However, when they were
engaged with antigen-presenting target cells, the pathway was not activated, and K562
cells were not able to produce the Nanoluc enzyme. In other words, when PMA, a PKC
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activator, was not added to the culture media, the engagement of K562 and target
antigens was not sufficient to activate the cell signaling pathway. As such, the PKC
enzymes were not activated by the insufficient initial Ca2+rise, which would have driven
the NFAT signaling pathway activity, in turn upregulating Nanoluc activity (45, 75).
These results should be taken into account when considering how other cells line can
be substituted with T cells for immunotherapies. Since the constant domains of the
signaling pathway of this study give the biofactory functionality, it is highly possible that
at least one of the constant domains did not perform its function. As a result, the
immunological synapse was not formed between K562 cells and target cells. An
immunological synapse is an interface between antigen-presenting cells and lymphocytes
such as T cells. For the integration of an immunological synapse, there are three broad
categories of receptors: antigens, adhesion molecules, and costimulatory molecules,
which are involved in T cell activation (46). Since Jurkat cells have all the machinery that
Primary T cells have, the immunological synapse between Jurkat-BF and OVCAR-3 cells
successfully formed. However, K562 cells do not express all the receptors that Jurkat
cells do. As a result, it was concluded that K562-BF was not a good choice to be
substituted with Primary T cells to recreate biofactory technology.
The ICAM-1 and LFA-3 adhesion molecules that are required to form an effective
immunological synapse are expressed by K562 cells. However, K562 cells do lack many
molecules that are necessary for the formation of the immunological synapse and the
activation of biofactories. The co-stimulatory signal, the second signal to activate an
immune response when engaged with antigen-presenting cells, depends on two co-
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stimulatory molecules expressed by T cells. One of them is CD28, which was expressed
by K562-BF as it was used to manipulate both biofactories. However, ICOS (Inducible
co-stimulator or CD278), the second co-stimulatory molecule for T cell proliferation and
cytokine secretion, was not expressed by K562 cells (46, 70).
Furthermore, K562 cells do not express the T cell receptors that enable T cells to
form the complex with CD3, the interaction of which would trigger an antigen-specific
immune response. Upon the formation of an immunological synapse, Lck (lymphocytespecific protein tyrosine kinase) phosphorylates and activates ZAP-70, a protein whose
activation is required for the induction of NFAT transcriptional activity (76). All these
molecules have a specific function in the formation of an immunological synapse and, in
consequence, the synthesis of therapeutic proteins. It is highly possible that the lack of
these molecules is the reason that K562-BF did not synthesize the Nanoluc enzyme when
engaging with target cells.
6.2 Function of Jurkat Cells that are Engineered to Express Chemokine Receptors
Chemokines are vital for many biological activities. The chemokine system
represents a potential target for immunotherapy, and it is vital in preventing healthy tissue
damage in the body. Chemokines, a large family of cytokines, control the migration and
positioning of immune cells within the body. In this part of the study, we generated a
second-generation Fr specific chimeric antigen receptor. The antigen recognition motif
was composed of an anti-folate receptor alpha antibody. The signaling domains consisted
of CD28 and CD3ζ.
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Jurkat cells were engineered to express this CAR receptor along with the CCR5 and
CCR7 chemokine receptors, in order to evaluate their migration and cytolytic ability on
cancer cells. Whereas the CAR receptor gave Jurkat cells the killing ability, the anti-Fr
antibody enabled them to recognize human ovarian cancer antigen, folate receptor alpha,
on OVCAR-3 cells. The rationale behind the selection of CCR5 and CCR7 chemokine
receptors was that CCL5 and CCL19, corresponding ligands of CCR5 and CCR7, are
highly produced in the ovarian tumor environment (77, 78, 79). As a proof of concept,
OVCAR-3 cells were also engineered to express CCL5 and CCL19 as their receptors
enable Jurkat cells to migrate and bind to their corresponding ligands. Target cells were
also engineered to express luciferase (luc2), which was measured to see whether
OVCAR-3 cells were alive. Since luciferase activity is ATP-dependent, dead cells cannot
produce bioluminescence. If the amount of luc2 were too high, it means OVCAR-3 cells
are alive and able to produce luc2 enzyme.
Figure 6 and Figure 7 show the luc2 expression of OVCAR-3 cells that were cocultured with Jurkat cells, expressing CCR5 and CCR7. The results and analysis
supported the theory that Jurkat CCR5+ and Fr-CAR Jurkat CCR7+ cells migrated
successfully towards OVCAR-3 CCL5+ and OVCAR-3 CCL19+ cells at 3 and 6 hours.
Both cells were found to be responsive to their corresponding ligands. Aldinucci et al.
(2020) and Cheng et al. (2020) supported the idea that CCR5/CCL5 and CCR7/CCL19
could be targeted in ovarian cancer (80,81). Both Jurkat cells, which express CCR5 and
CCR7, had the same cytolytic ability on target cells at different hours (3 and 6 hours). It
is therefore concluded that the cytolytic ability of Jurkat cells is not time dependent.
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7 Conclusion
Options for low-cost manufacturing and safer cell therapies were evaluated
throughout this research. To find a safer and cheaper alternative to CAR T cell therapies,
K562 cells were explored whether to be used instead of T cells. The rationale behind
using this cell line is that it has been approved as safe to be reinfused into the human
body by the FDA. Also, it is cheaper compared to T cells. Therefore, therapies generated
by K562 cells may be more affordable and safer for cancer patients.
Even though K562 cells were engineered with the same biofactory as Jurkat cells,
they were not able to synthesize Nanoluc protein as Jurkat cells did. Jurkat cells, an
immortalized line of T cells, have all the machinery that T lymphocytes have. As a result,
when they encounter antigen-presenting cells, an immunological synapse forms and
activates the biofactory. Upon activation of the biofactory, Jurkat cells synthesize
engineered proteins. K562 cells lack some of the molecules and receptors vital for the
formation of an immunological synapse. Thus, in situ upon interacting with antigenpresenting cells, intracellular signaling pathways were not activated. Therefore, the
signaling pathways whose activation is necessary to produce therapeutic proteins were
not activated either.
The study's second aim was to have effector cells migrated directly towards target
cells without harming the healthy sides of the body by using the chemokine system.
Effector cells and target cells were engineered to express chemokines and chemokine
receptors respectively to bind one another. This part of the study showed that the
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chemokine system is crucial to create safer therapies as they may prevent healthy tissue
damage.
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Appendices
Appendix A Specific Aim 1. K562 Biofactory Function
Table 2 shows NanoLuc expression amounts of chemically stimulated biofactories.
Table 2. Means and Standard Deviation of Nanoluc Expression Measurements of Jurkat
and K562 Biofactories
Effector
Cells
Jurkat BF
K562 BF

Mean (x106 a.u.)
PMA/Io
No treatment
82
2.4
57.4
0.421

Standard Deviation (x106 a.u.)
PMA/Io
No treatment
1.4
0.11
4.7
0.064

Table 3 shows NanoLuc expression amounts of biofactories that interact with cancer
cells.
Table 3. Means and Standard Deviation of Nanoluc Expression Measurements of Effector
and Target Cells, and Their Co-culture
Mean (x106 a.u.)
Co-culture
Combinations
JK-BF / OVCAR-3
JK-BF / A2780cis
K562-BF / OVCAR-3
K562-BF / A2780cis
JK-BF
OVCAR-3
K562-BF
A2780cis

Standard Deviation (x106 a.u.)

24 hrs

48 hrs

72 hrs

24 hrs

48 hrs

72 hrs

12
0.9
0.13
0.16
2.1
0.21
7.1
0.025

13.43
0.95
0.21
0.17
4.5
0.21
7.8
0.035

18.1
1.5
0.27
0.1
7.1
0.021
7.6
0.049

1.4
0.12
0.0092
0.03
0.4
0.003
0.19
0.0075

1.3
0.13
0.014
0.035
1.4
0.004
0.21
0.015

0.6
0.047
0.13
0.031
1.04
0.006
0.29
0.022
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Table 4 introduces the Nanoluc enzyme expressions of the biofactories that were cocultured with positive and negative controls.
Table 4. Nanoluc Expression Amounts After 24 hours of Co-culture of Target and
Effector Cells (a.u.)
Effecter
Cell
Number
12500

Target Cell
Number

JK-BF /
A2780cis

JK-BF /
OVCAR-3

K562-BF /
OVCAR-3

K562-BF /
A2780cis

976

0.59

10.57

0.18

0.164

12500

1953

0.74

13.71

0.14

0.135

12500

3906

0.75

13.84

0.13

0.152

12500

7812

0.92

13.8

0.14

0.173

12500

15625

0.95

15.69

0.12

0.144

12500

31250

1.12

14.31

0.107

0.113

12500

62500

1.34

14.88

0.094

0.111

12500

125000

1.63

16.751

0.125

0.152
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Appendix B Specific Aim 2. Function of CAR Jurkat Cells Engineered with
Chemokine Receptors
Table 5 and Table 6 introduce the Luc2 expression of the co-cultures of OVCAR-3 and
Jurkat cells at 3 and 6 hours.
Table 5. Luc2 Expression by Target Cells' Co-cultured with Effector Cells Expressing
CCR5+ and CCR5- at 3 and 6 hours
Receptor and
Ligand
Combinations
CCR5- / CCL5-

3 hours
Mean
Standard
(a.u.)
Deviation
(a.u.)
9329
1860

14849

CCR5+ / CCL5-

12356

4915

20516

1738

CCR5+ / CCL5+

2604

297

2498

311

Mean
(a.u.)

6 hours
Standard
Deviation
(a.u.)
220

Table 6. Luc2 Expression by Target Cells' Co-cultured with Effector Cells Expressing
CCR7+ and CCR7- at 3 and 6 hours
Receptor and
Ligand
Combinations
CCR7-/CCL19-

3 hours
Mean
Standard
(a.u.)
Deviation
(a.u.)
16267
1770

6 hours
Mean
Standard
(a.u.)
Deviation
(a.u.)
1629
1467

CCR7+/CCL19-

26871

2687

32467

2502

CCR7+/CCL19+

4627

394

3760
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